Claims
- 1. A compound represented by the following formula (I"): ##STR405## wherein R represents a hydrocarbon group or heterocyclic group which may be substituted; R.sup.5 and R.sup.6 independently represent hydrogen, halogen, a carboxyl group which may be esterified, or a hydrocarbon group which may be substituted; or a pharmaceutically acceptable salt thereof.
- 2. The compound according to claim 1, wherein the hydrocarbon group of R is an aliphatic chain hydrocarbon group or a monocyclic or condensed polycyclic aromatic hydrocarbon group.
- 3. The compound according to claim 2, wherein the aliphatic chain hydrocarbon group is a lower alkyl group.
- 4. The compound according to claim 2, wherein the monocyclic or condensed polycyclic aromatic hydrocarbon group is phenyl or naphthyl.
- 5. The compound according to claim 1, wherein the hydrocarbon group of R.sup.5 and R.sup.6 is an aliphatic chain hydrocarbon group or a monocyclic or condensed polycyclic aromatic hydrocarbon group.
- 6. The compound according to claim 5, wherein the aliphatic chain hydrocarbon group is a lower alkyl group.
- 7. The compound according to claim 5, wherein the monocyclic or condensed polycyclic aromatic hydrocarbon group is phenyl or naphthyl.
- 8. An endothelin receptor antagonist composition comprising as an active ingredient a compound represented by the following formula (I"): ##STR406## wherein R represents a hydrocarbon group which may be substituted; R.sup.5 and R.sup.6 independently represent hydrogen, halogen, a carboxyl group which may be esterified, or a hydrocarbon group which may be substituted; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- 9. The antagonist composition according to claim 8, wherein the hydrocarbon group of R is an aliphatic chain hydrocarbon group or a monocyclic or condensed polycyclic aromatic hydrocarbon group.
- 10. The antagonist composition according to claim 9, wherein the aliphatic chain hydrocarbon group is a lower alkyl group.
- 11. The antagonist composition according to claim 9, wherein the the monocyclic or condensed polycyclic aromatic hydrocarbon group is phenyl or naphthyl.
- 12. The antagonist composition according to claim 8, wherein the hydrocarbon group of R.sup.5 and R.sup.6 is an aliphatic chain hydrocarbon group or a monocyclic or condensed polycyclic aromatic hydrocarbon group.
- 13. The antagonist composition according to claim 12, wherein the aliphatic chain hydrocarbon group is a lower alkyl group.
- 14. The antagonist composition according to claim 12, wherein the monocyclic or condensed polycyclic aromatic hydrocarbon group is phenyl or naphthyl.
- 15. An cathepsin B inhibitor composition comprising as an active ingredient a compound represented by the following formula (I"): ##STR407## wherein R represents a hydrocarbon group which may be substituted; R.sup.5 and R.sup.6 independently represent hydrogen, halogen, a carboxyl group which may be esterified, or a hydrocarbon group which may be substituted; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- 16. A bone resorption suppressor composition containing as an active ingredient a compound represented by the following formula (I"): ##STR408## wherein R represents a hydrocarbon group which may be substituted; R.sup.5 and R.sup.6 independently represent hydrogen, halogen, a carboxyl group which may be esterified, or a hydrocarbon group which may be substituted; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
Priority Claims (2)
Number |
Date |
Country |
Kind |
4-067615 |
Mar 1992 |
JPX |
|
5-030872 |
Feb 1993 |
JPX |
|
FIELD OF THE INVENTION
The present invention relates to new compounds useful as exhibiting endothelin receptor antagonistic action, cathepsin B inhibiting action and bone resorption inhibitory action, a method of their production and use thereof.
Foreign Referenced Citations (3)
Number |
Date |
Country |
239064 |
Sep 1987 |
EPX |
60-246389 |
Dec 1985 |
JPX |
62-263185 |
Nov 1987 |
JPX |
Non-Patent Literature Citations (2)
Entry |
Biochemical Pharmacology, vol. 44, No. 6, Sep. 25, 1992, pp. 1201-1207. |
Chemical Abstracts, vol. 114, No. 3, Jan. 21, 1991, p. 696, Abstract No. 23848u. |